ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Proteolix Announces Clinical Results With Carfilzomib To Be Reported At ASH 2007 Annual Meeting
Proteolix, Inc.
announced that data from two Phase 1 clinical studies using
intravenous carfilzomib (PR-171) are to be presented at the 2007 American
Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, December
8-10, 2007. Carfilzomib is a potent and selective proteasome inhibitor
currently being investigated for the treatment of multiple myeloma,
lymphoma and solid tumors.
Robert Z. Orlowski, M.D., Ph.D., of the University of Texas, M.D.
Anderson Cancer Center, and Melissa Alsina, M.D., of the H. Lee Moffitt
Cancer Center and Research Institute, will be presenting data from two
Phase 1 clinical studies in relapsed and refractory hematologic
malignancies on Monday, December 10 beginning at 11:00 am and 11:30 am EST,
respectively, in a session entitled "Novel Therapies in Relapsed Myeloma."
Additional information about the 2007 ASH Annual Meeting can be found on
the ASH website at http://www.hematology.org/meetings/2007.
"We are very pleased that carfilzomib can be dosed on a consecutive-day
schedule in humans, as was predicted by animal studies," said Susan M.
Molineaux, Ph.D., President and CEO of Proteolix. "These early results
showing single-agent activity in myeloma indicate the potential of this
product candidate to help persons afflicted with the disease. We look
forward to data throughout 2008 from ongoing Phase 1b and 2 studies in
multiple myeloma, lymphoma and solid tumors."
About Proteolix
Proteolix, Inc. is a biopharmaceutical company dedicated to
discovering, developing and marketing pharmaceutical products that target
certain cancer and immunological conditions by inhibiting the proteasome
and thereby disrupting protein turnover in cells. In addition to its lead
product candidate, carfilzomib (PR-171), which is delivered intravenously
and is currently in multiple clinical trials to evaluate its safety and
efficacy in different types of cancer, Proteolix is developing
next-generation proteasome inhibitors, including an oral proteasome
inhibitor and a selective immunoproteasome inhibitor, to expand the
therapeutic potential of this target class. Proteolix is headquartered in
South San Francisco. For more information, please visit the Company's
website at http://www.proteolix.com.
Proteolix, Inc.
http://www.proteolix.com
Proteolix Announces clinice rezultate cu Carfilzomib sã fie raportate de cenuºã La reuniunea anualã 2007 - Proteolix Announces Clinical Results With Carfilzomib To Be Reported At ASH 2007 Annual Meeting - articole medicale engleza - startsanatate